SCHEDULE: Cystic Fibrosis Foundation Updates Stake in BiomX

Cystic Fibrosis Foundation reports a slight decrease in its beneficial ownership of BiomX Inc. common stock to 1.47%.

Summary

• The Cystic Fibrosis Foundation has filed an amendment to its Schedule 13G, reporting its beneficial ownership of BiomX Inc. common stock.
• As of June 30, 2026, the Foundation beneficially owns 174,276 shares of BiomX Inc. common stock.
• This represents 1.47% of the class of securities.
• The Foundation has sole voting power and sole dispositive power over these shares.
• This filing is an amendment (Amendment No. 5) to a previous filing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership without significant new financial or strategic information.

Positives

• The Cystic Fibrosis Foundation continues to hold a stake in BiomX Inc., indicating ongoing support or investment.
• The Foundation exercises sole voting and dispositive power, suggesting clear control over its investment.

Negatives

• The beneficial ownership has decreased slightly from a previous filing, though the exact previous percentage is not detailed here.
• The filing does not provide any new financial performance data or strategic updates for BiomX Inc.

Risks

• The filing does not explicitly mention any new risks related to BiomX Inc.'s operations or the Foundation's investment.

Future Outlook

No specific future outlook or guidance for BiomX Inc. is provided in this filing.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. This filing indicates a minor adjustment in the Cystic Fibrosis Foundation's passive investment in BiomX Inc., a biotechnology company, without signaling any major shift in strategy or market sentiment for the sector.

Stakeholder Impact

• Shareholders: The slight decrease in ownership by a significant holder may be noted, but without further context, the immediate impact on share price is likely minimal.
• BiomX Inc.: The filing confirms the ongoing passive investment by the Cystic Fibrosis Foundation, which can be seen as a stable, albeit small, shareholder.

Next Steps

• The Cystic Fibrosis Foundation will continue to file amendments to Schedule 13G as required by SEC regulations based on changes in its beneficial ownership of BiomX Inc. securities.

Key Dates

Keywords

BiomX Inc., Cystic Fibrosis Foundation, Schedule 13G, Beneficial Ownership, Common Stock, Investment Update